This invention provides a compound of the formula (I): ##STR00001## or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R.sup.4 are independently selected from H and C.sub.1-4 alkyl ; R.sup.5 is H, C.sub.1-4 alkyl, etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.